Biotech | September 12, 2025
iRegene Therapeutics secures series B+ financing
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Subscribe To Our Newsletter & Stay Updated
